Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Bolt Biotherapeutics ( (BOLT) ) is now available.
On October 1, 2025, Bolt Biotherapeutics announced a restructuring plan to reduce operating expenses, including a 50% workforce reduction, to extend its cash runway into 2027. The company also provided an update on its Phase 1 study of BDC-4182, observing a strong immune response at initial dose levels and planning to modify the trial protocol for step-up dosing, with initial clinical data expected in the third quarter of 2026.
The most recent analyst rating on (BOLT) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Bolt Biotherapeutics stock, see the BOLT Stock Forecast page.
Spark’s Take on BOLT Stock
According to Spark, TipRanks’ AI Analyst, BOLT is a Neutral.
Bolt Biotherapeutics faces significant challenges with profitability and cash flow inefficiencies, reflected in a low financial performance score. Technical analysis shows moderate bullish momentum, but valuation remains unattractive due to ongoing losses. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on BOLT stock, click here.
More about Bolt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment. The company leverages its expertise in myeloid biology and cancer drug development, with a pipeline that includes BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) targeting claudin 18.2, and strategic collaborations with Genmab and Toray.
Average Trading Volume: 17,502
Technical Sentiment Signal: Sell
Current Market Cap: $10.86M
See more data about BOLT stock on TipRanks’ Stock Analysis page.